Corporate News – Cg Oncology (CGON)
Trading Summary (24‑Hour Period Ending 03:44 AM CET, Wednesday 21 Oct 2026)
| Item | Value |
|---|---|
| Current price | USD 61.93 |
| Price change | +0.18 % |
| Market capitalisation | USD 5.3 bn |
| 24‑hour volume | USD 72.9 mn |
| Shares outstanding | 88.7 mn |
| 200‑day simple moving average | USD 65.19 |
| 52‑week high | USD 80.97 (19 Aug 2026) |
| 52‑week low | USD 35.80 (11 Nov 2025) |
| Monthly performance (last month end) | –23.37 % |
Recent Performance of Peer Stocks
| Ticker | Current price | % change (last 24 h) | Market capitalisation | P/E ratio (if available) |
|---|---|---|---|---|
| FLR (Fluor) | USD 45.18 | –0.81 % | USD 6.3 bn | – |
| GLXY (Galaxy Digital) | USD 15.76 | –2.60 % | USD 6.3 bn | – |
| EPAM (Epam) | USD 130.68 | +4.25 % | USD 6.3 bn | 16.44 |
| SWX (Southwest Gas) | USD 89.12 | 0 % | USD 6.3 bn | 22.4 |
| IOVA (Iovance Biotherapeutics) | USD 14.86 | +4.33 % | USD 6.4 bn | – |
Company Overview
CG Oncology, Inc.
- Industry: Biopharmaceuticals (Late‑stage development)
- Headquarters: Irvine, United States
- Primary Focus: Development and commercialization of a bladder‑sparing therapeutic for bladder cancer patients.
- Exchange: Nasdaq (Ticker: CGON)
- Website: www.cgoncology.com
- IPO Date: Scheduled for 25 January 2024
The company’s recent trading activity indicates modest gains on the day, while the overall market performance for the month has declined by nearly a quarter. The 200‑day moving average remains above the current price, suggesting a medium‑term downtrend. Peer companies in the sector show mixed results, with Epam and Iovance Biotherapeutics experiencing notable gains.
